Patents by Inventor Noriyuki Kinoshita
Noriyuki Kinoshita has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9198904Abstract: The present invention relates to a pharmaceutical composition for oral administration comprising a modified release portion containing tamsulosin or a pharmaceutically acceptable salt thereof, and an immediate release portion containing solifenacin or a pharmaceutically acceptable salt thereof and a hydrophilic substance. In the pharmaceutical composition, the dissolution rate of each drug (in particular, solifenacin contained in the immediate release portion) is similar to those of the current single drug formulations, and the maximum percentage of drag dissolution of each drug (in particular, solifenacin contained in the immediate release portion) is 90% or more. Therefore, the pharmaceutical composition is a single formulation (i.e., a combined formulation) with a bioavailability equivalent to those of the current single drug formulations.Type: GrantFiled: February 2, 2010Date of Patent: December 1, 2015Assignee: ASTELLAS PHARMA INC.Inventors: Takehiko Yasuji, Noriyuki Kinoshita, Hiroyuki Yoshino, Shuuya Kawahama, Kazuhiro Sako, Akio Sugihara
-
Publication number: 20110128557Abstract: There is provided a tablet printing apparatus that can perform printing at a high speed on tablets arbitrarily supplied in volume at irregular intervals and has a high printing quality. A tablet printing apparatus 1 for multicolor printing on tablets T comprises a conveying belt 24 for conveying the tablets T in a moving direction A1-A2, an inkjet printer 42 disposed in the middle of the moving direction A1-A2 of the conveying belt 24 for performing non-contact printing onto surfaces of the tablets T conveyed by the conveying belt 24, an encoder 28 and a tablet sensor 29 for detecting moving positions of the tablets T conveyed by the conveying belt 24, and a unit control substrate 32 for controlling printing timing on the tablets T of the inject printer 42 or 46 based on the moving conditions or/and the moving positions of the tablets T detected by the encoder 28 and the tablet sensor 29.Type: ApplicationFiled: August 22, 2008Publication date: June 2, 2011Applicants: ASTELLAS PHARMA INC., DAIICHI JITSUGYO CO., LTD., DAIICHI JITSUGYO VISWILL CO., LTD., MASTERMIND CO., LTD.Inventors: Noriyuki Kinoshita, Takao Mizumoto, Keizo Baba, Takashi Nishizato, Syuya Kawahama, Hideyuki Tomoda, Yoshihide Muramatsu, Shiro Hatano, Fumihiro Ogawa, Chizuo Ozawa
-
Publication number: 20100233260Abstract: The present invention relates to a pharmaceutical composition for oral administration comprising a modified release portion containing tamsulosin or a pharmaceutically acceptable salt thereof, and an immediate release portion containing solifenacin or a pharmaceutically acceptable salt thereof and a hydrophilic substance. In the pharmaceutical composition, the dissolution rate of each drug (in particular, solifenacin contained in the immediate release portion) is similar to those of the current single drug formulations, and the maximum percentage of drag dissolution of each drug (in particular, solifenacin contained in the immediate release portion) is 90% or more. Therefore, the pharmaceutical composition is a single formulation (i.e., a combined formulation) with a bioavailability equivalent to those of the current single drug formulations.Type: ApplicationFiled: February 2, 2010Publication date: September 16, 2010Applicant: Astellas Pharma Inc.Inventors: Takehiko Yasuji, Noriyuki Kinoshita, Hiroyuki Yoshino, Shuuya Kawahama, Kazuhiro Sako, Akio Sugihara
-
Patent number: 6844193Abstract: Disclosed herein are compositions and methods which are useful in the identification and isolation of components involved in transmembrane receptor-mediated signaling. Such components include the receptors themselves (e.g., tyrosine kinase receptors, cytokine receptors and tyrosine phosphatase receptors), as well as ligands which bind the receptors and modulators of the downstream intracellular catalytic event which characterizes receptor-mediated signalling. Two novel ligands for the FGF receptor and the nucleotide sequences encoding them are also described.Type: GrantFiled: December 10, 2001Date of Patent: January 18, 2005Assignee: President and Fellows of Harvard CollegeInventors: Marc W. Kirschner, Noriyuki Kinoshita
-
Publication number: 20020090651Abstract: Disclosed herein are compositions and methods which are useful in the identification and isolation of components involved in transmembrane receptor-mediated signaling. Such components include the receptors themselves (e.g., tyrosine kinase receptors, cytokine receptors and tyrosine phosphatase receptors), as well as ligands which bind the receptors and modulators of the downstream intracellular catalytic event which characterizes receptor-mediated signalling. Two novel ligands for the FGF receptor and the nucleotide sequences encoding them are also described.Type: ApplicationFiled: December 10, 2001Publication date: July 11, 2002Applicant: President and Fellows of Harvard CollegeInventors: Marc W. Kirschner, Noriyuki Kinoshita
-
Patent number: 6399386Abstract: Disclosed herein are compositions and methods which are useful in the identification and isolation of components involved in transmembrane receptor-mediated signaling. Such components include the receptors themselves (e.g., tyrosine kinase receptors, cytokine receptors and tyrosine phosphatase receptors), as well as ligands which bind the receptors and modulators of the downstream intracellular catalytic event which characterizes receptor-mediated signalling. Two novel ligands for the FGF receptor and the nucleotide sequences encoding them are also described.Type: GrantFiled: February 18, 2000Date of Patent: June 4, 2002Assignee: President and Fellows of Harvard CollegeInventors: Marc W. Kirschner, Noriyuki Kinoshita
-
Patent number: 6080718Abstract: Disclosed herein are compositions and methods which are useful in the identification and isolation of components involved in transmembrane receptor-mediated signaling. Such components include the receptors themselves (e.g., tyrosine kinase receptors, cytokine receptors and tyrosine phosphatase receptors), as well as ligands which bind the receptors and modulators of the downstream intracellular catalytic event which characterizes receptor-mediated signalling. Two novel ligands for the FGF receptor and the nucleotide sequences encoding them are also described.Type: GrantFiled: June 23, 1997Date of Patent: June 27, 2000Assignee: President and Fellows of Harvard CollegeInventors: Marc W. Kirschner, Noriyuki Kinoshita
-
Patent number: 6066460Abstract: The invention provides a method for isolating nucleic acids encoding proteins comprising a signal peptide, e.g., a secreted protein. The method of the invention comprises isolating an RNA molecule associated with an endoplasmic reticulumn membrane preparation under conditions wherein the RNA is at least partially translated. The invention also provides a library of nucleic acids encoding proteins comprising a signal peptide, individual nucleic acids isolated according to the method of the invention, peptides encoded thereby, pharmaceutical compositions comprising such and kits for performing the method of the invention.Type: GrantFiled: July 24, 1998Date of Patent: May 23, 2000Assignee: President and Fellows of Harvard CollegeInventors: Marc W. Kirschner, Noriyuki Kinoshita
-
Patent number: 5955288Abstract: Disclosed herein are compositions and methods which are useful in the identification and isolation of components involved in transmembrane receptor-mediated signaling. Such components include the receptors themselves (e.g., tyrosine kinase receptors, cytokine receptors and tyrosine phosphatase receptors), as well as ligands which bind the receptors and modulators of the downstream intracellular catalytic event which characterizes receptor-mediated signalling.Type: GrantFiled: October 18, 1996Date of Patent: September 21, 1999Assignee: President and Fellows of Harvard CollegeInventors: Marc W. Kirschner, Noriyuki Kinoshita
-
Patent number: 5766923Abstract: Disclosed herein are compositions and methods which are useful in the identification and isolation of components involved in transmembrane receptor-mediated signaling. Such components include the receptors themselves (e.g., tyrosine kinase receptors, cytokine receptors and tyrosine phosphatase receptors), as well as ligands which bind the receptors and modulators of the downstream intracellular catalytic event which characterizes receptor-mediated signalling. Two novel ligands for the FGF receptor and the nucleotide sequences encoding them are also described.Type: GrantFiled: May 15, 1995Date of Patent: June 16, 1998Assignee: President & Fellows of Harvard CollegeInventors: Marc W. Kirschner, Noriyuki Kinoshita
-
Patent number: 5573944Abstract: Disclosed herein are compositions and methods which are useful in the identification and isolation of components involved in transmembrane receptor-mediated signaling. Such components include the receptors themselves (e.g., tyrosine kinase receptors, cytokine receptors and tyrosine phosphatase receptors), as well as ligands which bind the receptors and modulators of the downstream intracellular catalytic event which characterizes receptor-mediated signalling.Type: GrantFiled: July 22, 1994Date of Patent: November 12, 1996Assignee: President and Fellows of Harvard CollegeInventors: Marc W. Kirschner, Noriyuki Kinoshita